Therapeutic Applications of Interleukin 24 (IL24): A Review
Abstract
Fisher’s group identified melanoma differentiation-associated protein-7 (MDA-7) upon discovery of cell surface receptor MDA-7 renamed Interleukin 24 (IL24).It has three N-glycosylation sites. IL24 signals
through receptors. Binding of IL24 to receptors leads to the activation of STAT-3 and STAT-1. IL 24 induces the secretion of high level of Interferon Gamma (IFN-ã) ,IL6 and tumor necrosis factor alpha (TNF-á) and low levels of IL1,IL12 and granulocyte macrophage colony stimulating factor (GM-CSF) from human peripheral blood mononuclear cells(PBMC). IL24 has growth suppressive properties in a wide variety of human cancer cell lines without inducing harmful effects in normal cells. This review is focused on the role of IL 24 on tumor cell biology and its potential therapeutic applications.
Keywords: Melanoma differentiation, Protein, Therapeutics, Interleukin, N-glycosylation, Cancer.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
